I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

A number of stocks jumped in the afternoon session after markets continued to rally as investor optimism grew for a potential ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

We are not close. After my father passed, she kicked us to the curb - not only financially but also emotionally and as a parent. Even though I was 20 when he died, I grew up in a family where we were ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...

Upstart's growth following its 2023/2024 slowdown looks like it’s going to stick this time around. Yes, MercadoLibre missed last quarter's earnings expectations. Now take a step back and look at the ...